229 results on '"Strupp, C."'
Search Results
2. Assessing in vitro dermal absorption of dry residues of agrochemical sprays using human skin within OECD TG 428
3. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML
4. Assessment of an extended dataset of in vitro human dermal absorption studies on pesticides to determine default values, opportunities for read-across and influence of dilution on absorption
5. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias
6. P094 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
7. P089 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
8. Assessment of in vitro human dermal absorption studies on pesticides to determine default values, opportunities for read-across and influence of dilution on absorption
9. Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification
10. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)
11. Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma
12. Vertebral fractures in multiple myeloma: first results of assessment of fracture risk using dynamic contrast-enhanced magnetic resonance imaging
13. Thalidomide for the treatment of patients with myelodysplastic syndromes
14. Independent validation of the MDS comorbidity score (MDS-CI): V956
15. Prognostic Factors and their Relevance in Different Subgroups of Myelodysplastic Syndromes - An Analysis of 2553 Patients from the Düsseldorf MDS Registry: V373
16. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup
17. Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome
18. Treatment of Acute Myeloid Leukemia with Valproic Acid Alone or in Combination with All-trans-Retinoic Acid: O392
19. Therapy-Related Myelodysplastic Syndromes: Characteristics in a Consecutive Series of 121 Patients: O358
20. Valproic Acid Alone or in Combination with All-trans-Retinoic Acid (ATRA) for the Treatment of Myelodysplastic Syndromes: O357
21. Thalidomide for the treatment of idiopathic myelofibrosis
22. Bone marrow microcirculation analysis by dynamic contrast-enhanced MR imaging in patients with myelodysplastic syndromes during thalidomide: P674
23. Cytogenetic response to thalidomide treatment in three patients with MDS: P680
24. Treatment of the 5q-syndorme with all-trans-retinoic acid: A phase II study of the German MDS study group: P667
25. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid: P668
26. Low-dose cytarabine cyclical maintenance in the 5q-syndrome: A case report: P666
27. No evidence of increasing incidence of myelodysplastic syndromes: V415
28. Transcription profile of hematopoietic CD34+ cells from patients with myelodysplastic syndrome: 912
29. Thalidomide for the treatment of myelodysplastic syndromes (MDS): 234
30. How to identify very-low-risk patients with myelodysplastic syndromes (MDS): 223
31. Response to combination therapy with valproic acid and alltrans retinoic acid in a patient with sAML/MDS: 228
32. Thalidomide for the treatment of osteomyelofibrosis: 88
33. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a ‘non-clonal’ pattern of X-chromosome inactivation in bone marrow cells
34. P124 Matched pair analysis of conventional regimens versus hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes – an analysis from the Duesseldorf MDS Registry
35. P009 Incidence and prevalence of myelodysplastic syndromes (MDS) in Duesseldorf 1996–2005
36. C007 Validation of the WHO proposals for the classification of unclassifiable myelodysplastic syndromes
37. C006 Detailed morphologic findings in 2773 patients with myelodysplastic syndromes
38. C004 Relevance of prognostic factors in different subgroups of myelodysplastic syndromes
39. 257 - Transfusion Need and Comorbidities are Independent Prognostic Parameters in Low Risk MDS Patients
40. 255 - Patients with IPSS-R Intermediate Risk can be Separated Into Three Risk Groups
41. 129 - Myelodysplastic Syndromes Showing Slight Monocytic Marrow Proliferation Are Prone to Progress to CMML
42. 124 - Who Classification 2016 for the Myelodysplastic Syndromes (MDS): Main Changes
43. P772: PROGNOSTIC IMPACT OF DISEASE‐RELATED RISK FACTORS AND TREATMENT APPROACHES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS)
44. P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY.
45. 317 ASXL1 MUTATION IS ASSOCIATED TO LOWER PLATELET COUNTS AND DECREASED BONE MARROW CELLULARITY IN MDS
46. 240 DYSPLASIAS REVISITED – CONSIDERATIONS FOR A MULTIDIMENSIONAL APPROACH TO HETEROGENEITY OF MDS: DATA ON 1979 PATIENTS FROM THE GERMAN AUSTRIAN DATA BASE
47. 119 UPDATE ON THE MULTICENTER MDS BIOREGISTRY PROJECT OF THE “KREBSHILFE-VERBUNDFORSCHUNGSPROJEKT MDS” OF THE GERMAN MDS STUDY GROUP
48. Myelodysplastische Syndrome.
49. Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide
50. P-255 Inclusion criteria of clinical trials do not meet the real MDS population. A registry-based simulation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.